Thriva, founded in 2016, offers at-home blood testing that lets customers monitor biomarkers such as cholesterol. The company pairs its testing service with personalized health plans and a line of high-quality supplements. It has scaled partnerships with hospitals and other healthcare providers to broaden its care pathways. Thriva reports processing more than 115,000 at-home blood tests since launch, and says 76% of users improved at least one biomarker between tests. The startup is headquartered in London, has grown its team to about 50 people, and is claiming 100% year-on-year growth. Recent fundraising has increased its financial runway and supported continued product and partnership expansion. Thriva provides at-home testing kits processed by UKAS-accredited laboratories that deliver clinical-grade insights based on the latest research. Its kits analyse vitamins, minerals, hormone function and indicators of heart disease and diabetes to help customers understand and track internal health. The company reports it has served over 100,000 people and employs 35 team members at its London headquarters. Founded in 2016 by Hamish Grierson, Eliot Brooks and Tom Livesey, Thriva has raised £7.5m since launch. In July 2019 it secured £6m in a Series A round from investors including Pembroke VCT and Guinness Asset Management. The company intends to use the funds to continue to expand operations and broaden its business reach. Thriva provides a consumer-facing at-home finger-prick blood test that returns lab results within 48 hours and presents users with a dashboard to track health changes over time. The company applies machine learning to an expanding dataset to deliver insights and predictions from biochemical markers. Thriva plans to use new funding to broaden its test range to include gut health, heavy metals and hormones. CEO Hamish Grierson frames the mission as making biochemical tracking as normal as counting steps or weighing oneself. The service targets the “worried well” and more scientifically minded users who value bona fide blood-test results over generic wellness advice. The article notes risks around a typical drop in user engagement after a few months and suggests integration with national health services would be a long shot.

Total raised

$14M

Funding rounds

3

Latest round

Series A

Latest activity

May 2020